DHA Supplementation in Patients With STGD3

Utah System of Higher Education (USHE)

Status: Completed

Conditions: Dominantly Inherited Stargardt's Disease (STGD3)

Treatments: Dietary Supplement: Over the counter DHA/EPA dietary supplementation

Study type: Interventional

Funder types: Other

Identifiers

NCT00420602

IRB 19676

Details and patient eligibility

About

We have found that biomarkers of long-term elevated dietary intake of omega-3 fatty acids such as DHA and EPA are inversely associated with severity of disease phenotype in STGD3 patients. Therefore, the purpose of this study is to follow STGD3 patients as they supplement their diets with DHA/EPA.

Enrollment: 11 patients

Sex: All

Ages: 18 to 105 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All Moran Eye Center patients with STGD3

Exclusion criteria

• All others

Trial design

Primary purpose: Prevention

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

11 participants in 1 patient group

Single Arm, Open Label

Other group

Description:

Single Arm, Open Label

Treatment:

Dietary Supplement: Over the counter DHA/EPA dietary supplementation